Lynn M. Schuchter, MD, examines the transformation of adjuvant therapy for Stage III/IV melanoma, with an overview of relevant clinical trials—including EORTC 18071, EORTC 1325/Keynote-54 and Checkmate-238—as well as the efficacy and safety of the agents involved in these studies, ipilimumab, nivolumab, pembrolizumab, dabrafenib and trametinib. Chief of the Division of Hematology Oncology, Dr. Schuchter also provides an update on current practice and future directions for melanoma care at Penn Medicine.